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Abstract
Background: Adiponectin, secreted mainly by mature adipocytes, is a protein with insulin-sensitising and anti-
atherogenic effects. Human adiponectin is encoded by the ADIPOQ gene on the chromosomal locus 3q27.
Variations in ADIPOQ are associated with obesity, type 2 diabetes (T2DM) and related phenotypes in several
populations. Our aim was to study the association of the ADIPOQ variations with body weight, serum adiponectin
concentrations and conversion to T2DM in overweight subjects with impaired glucose tolerance. Moreover, we
investigated whether ADIPOQ gene variants modify the effect of lifestyle changes on these traits.
Methods: Participants in the Finnish Diabetes Prevention Study were randomly assigned to a lifestyle intervention
group or a control group. Those whose DNA was available (n = 507) were genotyped for ten ADIPOQ single
nucleotide polymorphisms (SNPs). Associations between SNPs and baseline body weight and serum adiponectin
concentrations were analysed using the univariate analysis of variance. The 4-year longitudinal weight data were
analysed using linear mixed models analysis and the change in serum adiponectin from baseline to year four was
analysed using Kruskal-Wallis test. In addition, the association of SNPs with the risk of developing T2DM during the
follow-up of 0-11 (mean 6.34) years was analysed by Cox regression analysis.
Results: rs266729, rs16861205, rs1501299, rs3821799 and rs6773957 associated significantly (p < 0.05) with body
weight at baseline and in the longitudinal analyses. The rs266729 C allele and the rare minor alleles of rs2241766
and rs2082940 were associated with an increased adjusted hazard ratio of developing T2DM. The differences in
baseline serum adiponectin concentrations were seen according to rs16861210, rs17366568, rs2241766, rs6773957
and rs2082940 and differences in the change of serum adiponectin levels from baseline to the four year
examination were seen according to rs16861205, especially in subjects who were able to lose weight during the
first year of intervention.
Conclusions: These results from the Finnish Diabetes Prevention Study support the concept that genetic variation
in ADIPOQ locus contributes to variation in body size and serum adiponectin concentrations and may also modify
the risk of developing T2DM.
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Type 2 diabetes (T2DM) and obesity are increasing
worldwide. Although this is mainly due to environmen-
tal factors, such as changes in diet and lifestyle, much
evidence for genetic predisposition to these complex
traits exist [1].
Adiponectin is an adipokine, and its plasma levels are
decreased in obesity [2], T2DM [3], insulin resistance
[4], dyslipidemia [5], and coronary artery disease (CAD)
[6]. In humans, weight reduction increases serum adipo-
nectin levels [3,7], and in mice, chronic administration
of recombinant adiponectin leads to enhanced fatty acid
oxidation, and weight loss [8] with beneficial effects on
lipid metabolism and insulin sensitivity [9]. Furthermore,
adiponectin knock-out mice are highly sensitive to diet
induced insulin resistance [10].
Adiponectin is encoded by the ADIPOQ gene on chro-
mosome 3q27, a region identified as susceptibility locus for
the metabolic syndrome and T2DM by genome wide scans
[11-13]. In various study populations, ADIPOQ SNPs and
haplotypes associate with phenotypes related to obesity
[14-18], insulin resistance and T2DM [14-16,19-27] and
serum adiponectin levels [14,16,18,21,23,28-34]. However,
possibly due to differences in metabolic or ethnic back-
grounds of the participants in different studies, the results
of previous genetic association studies are conflicting. In
addition, most of the studies performed so far have been
cross-sectional and have only included few SNPs in the
region of ADIPOQ. The aim of the present study was to
p r o v i d es u p p o r t i v ee v i d e n c ef o rt h ei n v o l v e m e n to f
ADIPOQ variation in T2DM and obesity related pheno-
types and serum adiponectin levels in the prospective
Finnish Diabetes Prevention Study (DPS). Moreover, the
aim was to examine whether ADIPOQ SNPs modify the
effect of lifestyle changes on these traits.
Methods
Subjects and study design
The DPS is a randomised, controlled multicentre study
with five participating clinics in Finland. The study
design has been described in detail earlier [35,36]. The
main inclusion criteria were BMI > 25 kg/m
2, age 40-64
years, and impaired glucose tolerance (IGT) based on
the mean value of two consecutive oral glucose toler-
ance tests (OGTTs). The diagnosis of IGT and T2DM
were based on WHO 1985 criteria [37]. IGT was
defined as fasting plasma glucose < 7.8 mmol/l and a
2-h plasma glucose 7.8-11.0 mmol/l (OGTT, glucose
load 75 g). A total of 522 subjects (BMI 31.1 ± 4.6 kg/
m
2) were randomly allocated into one of the two
groups: an intensive diet and exercise intervention
group or a control group. Randomisation was stratified
according to the clinic attended, sex and 2-hour plasma
glucose concentration. The study protocol was approved
by Ethics Committee of the National Public Health
Institute in Helsinki, Finland and a written informed
consent was received from all subjects [35,36]. We cer-
tify that all applicable institutional and governmental
regulations concerning the ethical use of human volun-
teers were followed during this research.
Intervention
The subjects in the intervention group received indivi-
dualized counselling on diet and exercise [38]. The five
goals of the intervention were: ≥ 5% or more reduction
in body weight, reduction in the intake of total fat to
≤30% and of saturated fat to ≤ 10% of daily energy
intake, increase of the intake of dietary fibre to at least
15 g per 1000 kcal and moderate-to-vigorous exercise at
least 30 min per day. The subjects in the control group
received general information about healthy diet and
exercise at baseline.
Examinations
A medical history was recorded and a physical examina-
tion with anthropometric measurements was performed
at baseline and at each annual follow-up visit. Measure-
ments recorded at baseline and 1, 2, 3 and 4 year exami-
nations were used in the present study.
Assessment of glucose and insulin metabolism
A 2-h OGTT was performed at baseline and annually.
Plasma glucose and insulin samples were drawn at
0 min and 120 min during the OGTT with a glucose
load of 75 g. Plasma glucose was measured locally by
standard methods as previously described [36]. Serum
insulin was measured by RIA (Phadaseph Insulin RIA
100, Pharmacia Diagnostica, Uppsala, Sweden). The
intra-assay coefficient of variation was 5.3% and the
interassay coefficient of variation was 7.6%. The diagno-
sis of IGT was based on the mean value of two oral glu-
cose tolerance tests. A new diagnosis of diabetes (fasting
plasma glucose ≥7.8 mmol/l or 2-h plasma glucose
≥11.0 mmol/l) was confirmed by a second oral glucose
tolerance test.
Determination of adiponectin concentrations
Fasting serum adiponectin levels were measured using
an enzyme-linked immunosorbent assay (ELISA)
(B-Bridge International, Inc., San Jose, CA, USA), on
whole plasma stored at -80°C. The intra-assay and inter-
assay coefficients of variation were 5.5-7.9% and 6.5%,
respectively. Frozen serum samples for adiponectin mea-
surements were only available from subset of partici-
pants from three study clinics (n = 243 at baseline, and
n = 209 at 4-year examination). In altogether 190 sub-
jects both baseline and year four serum adiponectin
concentrations were measured.
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DNA sample was available from 507 subjects (166 men
and 341 women). Tagging SNPs with minimum minor
allele frequency of 5% were selected based on genotype
data of the Hapmap CEU population [39] by using the
Tagger algorithm [40] with rs2241766 and rs1501299,
selected based on previous literature, being forced into
the selection. Altogether, the ten SNPs selected for gen-
otyping covered 73% of the variation within ADIPOQ
region (20 kbp) with r
2 ≥ 0.8. Rs2241766 and rs1501299
w e r eg e n o t y p e du s i n gP C Rf o l l o w e db yS N a P s h o t
ddNTP Primer Extension Kit technique (ABI Prism;
Applied Biosystems) as described earlier [24].
Rs17366568 was genotyped using PCR-RFLP method.
The genomic DNA was amplified by PCR by using the
following primers: forward 5’-CCCAATAGTCAAA-
CATGTGC-3’ and reverse 5’-TCATCCTTGGAAGAC-
CAACC-3’ followed by digestion with restriction
enzyme MseI (New England Biolabs). Other SNPs were
genotyped with TaqMan Allelic Discrimination assays
according to manufacturer’s instructions by using the
ABI PRISM 7000 sequence detector (Applied Biosys-
tems, Foster City, CA). For a subset of randomly
selected samples (6.3%) genotyping was repeated in
order to calculate success rate.
Statistical analysis
The data were analysed with SPSS for Windows 14.0
(SPSS Inc, Chicago, IL). Chi square test was used to test
the departure of genotypes from Hardy-Weinberg equili-
brium (HWE) and the distribution of genotypes between
study groups. Skewed variables were transformed for
analysis and are reported as back-transformed geometric
means and 95% confidence intervals (CIs), or were ana-
lysed with nonparametric tests. Normally distributed
data are presented as mean ± SE. All analyses were car-
ried out using three inheritance models: additive, domi-
nant (common allele homozygotes compared with
heterozygotes and minor allele homozygotes), and reces-
sive (common allele homozygotes and heterozygotes
compared with minor allele homozygotes). The baseline
differences in continuous variables between genotypes
were evaluated with the univariate ANOVA, general lin-
ear model (GLM). Longitudinal weight data were exam-
ined using the linear mixed models analysis. Normality
was assessed by plotting the residuals. Association of the
SNPs with conversion to T2DM was analysed by using
Cox regression. Adjustments for age, sex, BMI, waist-to-
hip ratio (WHR), fasting plasma glucose and study
group (intervention or control) were made when appro-
priate. A multiple SNP analysis was performed for
groups of SNPs that associated with baseline weight,
baseline serum adiponectin levels and the risk of T2DM
by including all significant SNPs (coded as major allele
homozygotes vs. minor allele carriers) in the same statis-
tical model and then removing SNPs sequentially start-
ing from the least significant one. Sex-genotype or study
group-genotype interaction term was included in ana-
lyses when appropriate. When significant interaction
(p < 0.05) was observed, men and women or the study
groups were analysed separately. Change in serum adi-
ponectin concentration was calculated by subtracting
the baseline values from the fourth year values. Correc-
tion for multiple hypothesis testing for single SNP ana-
lyses was performed with false discovery rate (FDR)
method using Q value 1.0 software [41]. The q-values
were calculated separately for each trait, but all SNPs
and inheritance models were included in the same cal-
culations. The pair wise linkage disequilibrium (LD)
between individual SNPs was evaluated with Haploview
software (version 3.32; Broad institute, Cambridge, MA)
[42]. Haploblocks were defined using the default algo-
rithm [43].
Results
Table 1 shows the clinical and metabolic characteristics
of the study population.
Genotype frequencies and linkage disequilibrium (LD)
patterns
Ten SNPs were genotyped from the 507 DNA samples
of the DPS participants with an error rate of 0% and a
call rate of 100% in replicated samples for all markers.
The locations of the analysed variants are presented in
Table 1 Baseline characteristics, 1-year weight change
and 4-year serum adiponectin change in DPS participants
Sex (male/female) 166/341
Age (y) 55.33 ± 7.06 (507)
Weight (kg) 86.20 ± 14.19 (507)
BMI (kg/m
2) 31.25 ± 4.54 (507)
Waist circumference (cm) 101.22 ± 10.99 (505)
Fasting plasma glucose
(mmol/l)
6.14 ± 0.75 (507)
2-h plasma glucose (mmol/l) 8.88 ± 1.49 (507)
Fasting serum insulin (mU/l) 14.77 ± 7.40 (461)
2-h serum insulin (mU/l) 95.17 ± 65.10 (458)
Serum adiponectin (μg/ml) 8.47 ± 3.74 (237)
1-year weight change (kg) -2.736 ± 4.723 (506)
Intervention
group
-4.465 ± 4.976 (256)
Control group -0.965 ± 3.695 (250)
4-year adiponectin change
(μg/ml)
0.015 ± 2.135 (190)
Intervention
group
0.091 ± 2.245 (97)
Control group -0.063 ± 2.203 (93)
Values are mean ± SD (N); BMI, Body Mass Index
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2). As pre-
viously reported, we observed two LD blocks [31] with
rs266729 and rs16861205 constituting the block 1, and
rs1501299, rs3821799 and rs6773957 constituting the
block 2, while other SNPs remained between or outside
the blocks.
Genotype counts and allele frequencies are shown in
Table 2. All SNPs, except rs16861210, were in HWE (p <
0.05) in the entire DPS population. The deviation from
HWE could be explained as a chance finding due to low
f r e q u e n c yo ft h em i n o ra l l e l ea n dl i m i t e ds a m p l es i z eo f
DPS. Thus, rs16861210 was included in further analyses.
Genotype frequencies of rs16861205, rs3821799 and
rs2082940 differed significantly (p < 0.05) between the
intervention and control group of DPS. Again, this is
probably due to chance and these SNPs were included in
analyses, but all longitudinal data analyses were
performed separately in both study groups in addition to
analyses in the total study population.
Genotype associations with body weight
Rs266729, rs16861205, rs1501299, rs3821799 and
rs6773957 associated with baseline body weight, when
adjusted for age and sex (table 3). Furthermore, the
same SNPs associated with 4-year follow-up measure-
ments of weight, when analysed longitudinally with
adjustments for age, sex, study group and the time vari-
able. Similar associations between ADIPOQ SNPs and
baseline and 4-year measurements of BMI were seen
(data not shown). Genotype differences were mainly
seen by using additive and dominant inheritance models.
Individuals carrying the rs266729 G allele had higher
baseline body weight than those homozygous for
C allele. A sex-genotype interaction was found for
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Figure 1 ADIPOQ gene, locations of the genotyped variants and their pairwise linkage disequilibrium (LD) patterns.S c h e m a t i c
presentation of the ADIPOQ, indicating the locations of the analysed variants, the two observed haploblocks and the pairwise LD measures D’
(above) and r
2 (below). Grey boxes, untranslated region; black boxes, coding region; MAF, minor allele frequency.
Siitonen et al. BMC Medical Genetics 2011, 12:5
http://www.biomedcentral.com/1471-2350/12/5
Page 4 of 13weight and significant differences were observed in
women. Likewise, during the 4-year follow-up significant
differences in weight according to rs266729 were only
observed in women (p = 0.007/q = 0.038 for the domi-
nant inheritance model and p = 0.027/q = 0.309 for sex-
genotype interaction).
Rs16861205 G, rs1501299 G, rs3821799 C and
rs6773957 G alleles associated dose-dependently with
higher baseline body weight. The longitudinal data is
shown for rs3821799 in figure 2. Genotype differences
remained significant during the 4-year follow-up, when
the additive inheritance model was used (rs16861205:
p = 0.028/q = 0.049, rs1501299:p = 0.041/q = 0.049,
rs3821799: p = 0.002/q = 0.049, and rs6773957: p =
0.045/q = 0.049) and were even stronger when the
dominant inheritance model was used (rs16861205: p =
0.008/q = 0.049, rs1501299: p = 0.014/0.049, rs3821799:
p = 0.001/q = 0.049, and rs6773957: p = 0.014/q =
0.049). For rs3821799, the genotype differences were sig-
nificant also when the recessive inheritance model was
used. When the longitudinal analyses were performed
separately in the intervention and control group, geno-
type differences remained constant during the follow-up
in both groups, but were statistically significant only in
the control group.
We also conducted multiple SNP models analysis with
SNPs that associated individually with baseline body
weight. In a model including all five SNPs, a trend for
significance was observed for rs3821799 (p = 0.063).
When the least significant SNPs were removed sequen-
tially from the model, two SNPs remained in the final
model: rs3821799 (p = 0.007) and rs16861205 (p =
0.101).
Genotype associations with Type 2 Diabetes Incidence
Altogether 184 of 507 subjects converted from IGT to
T2DM during the follow-up of 0-11 (mean 6.34) years.
The association of the 10 ADIPOQ SNPs with the conver-
sion from IGT to T2DM was analysed by using Cox
regression models adjusting for baseline BMI, WHR, base-
line fasting plasma glucose and study group (Table 4).
T2DM was less likely developed in study participants
carrying rs266729 G allele. The adjusted hazard ratio
was 0.682 (95% CI 0.510-0.912, p = 0.010/q = 0.203) for
the G allele carriers compared with subjects with CC
genotype, 0.695 (95% CI 0.513-0.942, p = 0.019/q =
0.203) for CG genotype and 0.615 (95% CI 0.350-1.081,
p = 0.091/q = 0.330) for GG genotype. In addition, sub-
jects carrying the rare minor alleles of rs2241766 and
rs2082940 (G and T, respectively) had increased risk of
developing T2DM. The results were similar when a sta-
tistical model not adjusted for BMI or WHR was used
(data not shown).
Since the lifestyle intervention decreased the risk of
T2DM significantly in the DPS [36], the effects of each
SNP were examined for the intervention and control
groups separately. The genotype differences were similar
in both groups according to rs266729, but statistical sig-
nificance was reached only in the control group. Only
two subjects were homozygous for the rare alleles of
rs2241766 and rs2082940 and both were in the control
group. When dominant inheritance model was used, sig-
nificant differences were only seen in the control group
according to rs2241766.
In a multiple SNP model with rs266729, rs2241766
and rs2082940, only rs2766729 remained significant pre-
dictor of conversion from IGT to T2DM (adjusted
hazard ratio 0.693, 95% CI 0.518-0.928, p = 0.014 for
the G allele carriers compared with subjects with CC
genotype). A borderline significance was observed for
rs2241766 when it was included in the model with
rs266729 (p = 0.086).
Genotype associations with serum adiponectin levels
Baseline serum adiponectin levels differed significantly
according to five ADIPOQ SNPs, when adjustments
were made for age, sex and baseline WHR (Table 5):
rs16861210 (p = 0.029/q = 0.032 for the additive and
p = 0.008/q = 0.032 for the dominant inheritance
Table 2 ADIPOQ genotype counts and allele frequencies.
Genotypes
(count)
Allele freq
(%)
p/q
a p/q
b
rs266729 CC CG GG C G
219 240 48 66.9 33.1 0.124/0.683 0.509/0.300
rs16861205 GG GA AA G A
337 151 19 81.4 18.6 0.685/0.855 0.005/0.138
rs169861210 GG GA AA G A
471 33 3 96.2 3.8 0.007/0.683 0.279/0.195
rs17366568 GG GA AA G A
371 122 14 85.2 14.8 0.306/0.683 0.876/0.412
rs2241766 TT TG GG T G
460 45 2 95.2 4.8 0.431/0.683 0.107/0.138
rs1501299 GG GT TT G T
234 220 53 67.9 32.1 0.903/0.855 0.134/0.138
rs3821799 CC CT TT C T
149 255 103 54.5 45.5 0.748/0.855 0.017/0.138
rs17366743 TT TC T C
468 39 96.2 3.8 0.368/0.683 0.758/0.396
rs6773957 GG GA AA G A
206 233 68 63.6 36.4 0.869/0.855 0.071/0.138
rs2082940 CC CT TT C T
466 39 2 95.8 4.2 0.234/0.683 0.047/0.138
ap/q value for Hardy-Weinberg equilibrium.
bp/q value for differences in genotype frequencies between the study groups
of DPS.
Correction for multiple hypothesis testing was performed with FDR, denoted
as q-value.
Siitonen et al. BMC Medical Genetics 2011, 12:5
http://www.biomedcentral.com/1471-2350/12/5
Page 5 of 13model), rs17366568 (p = 0.003/q = 0.032 for the additive
and p = 0.0007/q = 0.032 for the dominant inheritance
model), rs2241766 (p = 0.056/q = 0.032 for TT vs. TG
genotype), rs6773957 (p = 0.016/q = 0.032 for the addi-
tive, p = 0.021/q = 0.032 for the dominant and p =
0.022/q = 0.032 for the recessive inheritance model) and
rs2082940 (p = 0.056/q = 0.032 for CC vs. CT geno-
type). Lower serum adiponectin concentrations were
associated with rs16861210 G allele, rs17366568 A allele,
rs2241766 TT genotype, rs6773957 G allele and
rs2082940 CC genotype. In addition, a significant sex-
genotype interaction was found for rs2241766 and
rs2082940 (p = 0.020/q = 0.279 for both). When men
and women were analysed separately, a significant asso-
ciation between rs2241766 and rs2082940 genotype and
serum adiponectin levels was seen only in men (p =
0.003/q = 0.131 for both SNPs).
In multiple SNP model including rs16861210,
rs17366568, rs6773957 and either rs2241766 or rs2082940,
the first two SNPs remained significantly associated with
baseline adiponectin levels (p = 0.012 and p = 0.003,
respectively).
Baseline serum adiponectin concentrations and T2DM risk
At r e n df o ral o w e rT 2 D Mr i s kw a ss e e nw i t hh a z a r d
ratio of 0.695 (0.451-1.072, p = 0.100) for those with
higher than median (6.250 for men and 8.815 for
women) serum adiponectin concentrations compared
with those with adiponectin lower than median.
Genotype associations with 4-year change in adiponectin
concentrations
Rs16861205 associated with 4-year change in serum adi-
ponectin concentrations (p = 0.040/q = 0.798 and p =
0.014/q = 0.798 for the additive and the dominant
inheritance models, respectively) (figure 3). The A allele
was dose dependently associated with increase in serum
adiponectin levels (AA: n = 9 and AG: n = 54) com-
pared with the GG genotype (n = 127). When study
groups were analysed separately, genotype differences
were similar, but statistical significance was not reached.
When individuals who lost weight (n = 144) or gained
weight (n = 45) during the first year of the intervention
were analysed as separate groups, statistically significant
differences in the 4-year change were seen only in those
Table 3 Significant associations between ADIPOQ SNPs and baseline body weight
p
a/q p
b/q
rs266729 (N) CC (219)
c CG, GG (288)
d
All 85.04 (83.33-86.79) 87.66 (86.09-89.25) 0.025/0.024 0.020/0.700
male 91.36 (88.60-94.21) 89.69 (87.26-92.19) 0.385/0.420
female 80.18 (78.16-82.25) 84.46 (82.63-86.33) 0.003/0.036
rs16861205 (N) GG (337) GA (151) AA (19)
All 87.66 (86.20-89.14) 84.37 (82.33-86.46) 83.86 (78.36-89.67) 0.023/0.024 0.528/0.684
GG (337) AA, AG (170)
All 87.65 (86.20-89.13) 84.31 (82.39-86.26) 0.006/0.024 0.302/0.684
rs1501299 (N) GG (234) GT (220) TT (53)
All 88.09 (86.37-89.84) 85.36 (83.63-87.13) 84.16 (80.80-87.66) 0.032/0.024 0.486/0.684
GG (234) GT, TT (273)
All 88.09 (86.37-89.84) 85.13 (83.56-86.72) 0.011/0.024 0.407/0.684
rs3821799 (N) CC (149) CT (255) TT (103)
All 89.63 (87.49-91.82) 85.64 (84.02-87.29) 83.99 (81.56-86.48) 0.001/0.024 0.187/0.700
CC (149) CT, TT (358)
All 89.63 (87.49-91.82) 85.16 (83.78-86.57) 0.0005/0.024 0.072/0.724
CC, CT (404) TT (103)
All 87.13 (85.80-88.48) 84.03 (81.59-86.55) 0.029/0.024 0.861/0.684
rs6773957 (N) GG (206) GA (233) AA (68)
All 88.31 (86.49-90.17) 85.29 (83.61-87.01) 84.98 (81.95-88.12) 0.033/0.024 0.200/0.700
GG (206) AA, AG (301)
All 88.31 (86.50-90.17) 85.22 (83.72-86.76) 0.009/0.024 0.172/0.684
Data are expressed as retransformed geometric mean (95% CI).
Correction for multiple hypothesis testing was performed with FDR, denoted as q-value.
a adjusted for age and sex.
b p for sex-genotype interaction.
c Men: N = 74, Women N = 145.
d Men: N = 92, Women N = 196.
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the additive inheritance model, p = 0.013/q = 0.725 for
the dominant inheritance model, figure 3 B). Like in the
whole study population, serum adiponectin concentra-
tions increased in subjects carrying the A allele.
Discussion
In the present study, we found novel associations
between ADIPOQ variations and body weight, the risk
of T2DM and serum adiponectin concentrations. The
results also support the existing view that genetic varia-
tion in the ADIPOQ influences metabolic and anthropo-
metric characteristics related to T2DM.
Body weight - SNPs in haploblocks 1 and 2
Rs266729 and rs1501299 are the most extensively stu-
died of the SNPs associating with body weight and BMI
in DPS. Earlier studies report associations to various
obesity related phenotypes for rs266729 [15,16,29] and
for rs1501299 [14,16,17].
We found that rs266729 G allele carriers had higher
weight compared with individuals with CC genotype at
baseline and a similar trend was seen during the 4-year
follow-up, especially in women. Significant association
that were seen more often in women than men may be
explained by larger number of female subjects in the
DPS. In contrast to our results, rs266729 C is a risk
allele for obesity related phenotypes in most study
populations [15,16]. Genotype differences according to
rs1501299 were seen in baseline weight as well as in
4-year follow-up. In agreement with this, the G allele
was associated with obesity related phenotypes in some
studies [14], but the T allele in others [16,17].
To our knowledge, no previous data concerning asso-
ciations of intronic SNPs rs16861205 and rs3821799,
and rs6773957, located in the 3’UTR, with obesity
related phenotypes exists. The strongest association was
observed for rs3821799 and it remained significant also
in multiple SNP analyses. During the 4-year follow-up,
the genotype differences remained constant in both
study groups. Thus, individuals with different ADIPOQ
genotypes did not respond differently to the lifestyle
modification regarding weight change.
Type 2 diabetes - rs266729, rs2241766 and rs2082940
We found significantly increased conversion rates from
IGT to T2DM for subjects homozygous for the
rs266729 C allele. The G allele, associated with higher
body weight, associated with lower T2DM risk in statis-
tical models with or without adjustment for obesity
related covariates. It seems therefore that the effect of
ADIPOQ variation on T2DM risk is independent of its
effect on body weight. According to previous studies
rs266729 G allele frequently associates with increased
risk of T2DM [15,23] and insulin resistance [16,44]. On
the other hand, the C allele was associated with
increased risk of T2DM in a German study population
[25] and with lower clamp-derived insulin sensitivity in
a cohort of Europid adolescents and their parents [26].
In addition, the rare minor alleles of rs2241766 and
rs2082940 associated with conversion to T2DM in DPS.
Rs2241766 is one of the most extensively studied ADI-
POQ SNPs. Consistent with our results, the G allele
associated with T2DM in cross-sectional studies [21],
and also with T2DM risk [24] and hyperglycemia
[19,20] in prospective studies. On the contrary, others
have reported that the T allele associated with elevated
insulin/glucose values and insulin resistance [14]. To
our knowledge, no previous studies have found associa-
tion between T2DM and rs2082940, which is in high
LD with rs2241766 (r
2 = 0.872). It is located in the 3’
UTR and its functional role is currently unknown. In
multiple SNP analyses rs266729 remained significant
predictor of T2DM risk. Thus at least one genetic signal
affecting T2DM risk exists in the ADIPOQ locus. When
the study groups were analysed separately, SNPs asso-
ciated with T2DM similarly in both study groups. Thus,
the effect of lifestyle intervention on T2DM was not
modified by the ADIPOQ SNPs studied.
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Figure 2 Body weight from baseline to year 4 according to
rs3821799. Data are predicted geometric means and 95% CI.
Additive (A) and dominant (B) inheritace models; p values are
adjusted for age, sex, study group and the time; Correction for
multiple hypothesis testing was performed with FDR, denoted as
q-value.
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Page 7 of 13Serum adiponectin levels - SNPs in intron1, exon 2 and in
3’UTR
Serum adiponectin levels are under strong genetic con-
trol [45,46]. A genome-wide scan of plasma adiponectin
levels provided evidence that variation in ADIPOQ gene,
especially rs2241766, rs1501299 and +2019A/- insertion/
deletion polymorphism, are responsible for linkage of
adiponectin levels to 3q27 in the Old Order Amish [28].
Moreover, a recent genome wide association study
found that rs17366568 explained 3.8% of variation in
adiponectin levels, while 6.7% of the variation was
explained by all SNPs in the ADIPOQ region [47]. In
another whole genome association analysis rs6773957
and rs3774261 associated strongly with adiponectin
levels [34]. Furthermore, rs6773957 and two promoter
SNPs (rs17300539 and rs822387) associated with higher
serum adiponectin levels and a trend for rs17366568
was also seen [33].
In our study, rs16861210, rs17366568 and rs6773957
associated strongly with baseline serum adiponectin
levels in a dose dependent manner. In multiple SNP
analyses the significance of rs6773957 was lost indicat-
ing LD with another, most likely rs17366568. To our
knowledge, no previous studies examining the associa-
tion between rs16861210 and adiponectin levels have
been published. Both rs16861210 and rs17366568 are
located in intron 1, but are not in strong LD with each
other and represent likely independent genetic signals
affecting serum adiponectin levels. Functional role of
either SNP is currently unknown, but interestingly,
three SNPs located immediately on either side of
rs17366568 were predicted to affect transcription factor
binding sites [47].
The association between rs2241766 and rs2082940
with baseline serum adiponectin remained borderline
significant in multi SNP analyses and may represent
Table 4 Hazard ratios for association of ADIPOQ SNP1, rs2241766 and rs2082940 with T2DM
SNP Genotype Entire DPS Intervention group Control group
N HR (95% CI), p
a/q N HR (95% CI), p
b/q N HR (95% CI), p
b/q
rs266729 CC 219 1 117 1 102 1
CG 240 0.695 (0.513-
0.942), 0.019/
0.203
121 0.733 (0.453-
1.185), 0.205/
0.616
119 0.661 (0. 444-
0.985), 0.042/
0.237
GG 48 0.615 (0.350-
1.081), 0.091/
0.330
21 0.400 (0.123-
1.300), 0.128/
0.616
27 0.743 (0.388-
1.422), 0.370/
0.818
CC 219 1 117 1 102 1
CG, GG 288 0.682 (0.510-
0.912), 0.010/
0.203
142 0.683 (0.428-
1.090), 0.110/
0.616
146 0.676 (0.464-
0.985), 0.041/
0.237
rs2241766 TT 460 1 231 1 229 1
TG 45 1.521 (0.944-
2.452), 0.085/
0.330
28 1.320 (0.625-
2.786), 0.466/
0.616
17 1.648 (0.881-
3.083), 0.118/
0.470
GG 2 5.448 (1.329-
22.333), 0.019/
0.203
0 - 2 4.993 (1.211-
20.598), 0.026/
0.237
TT 460 1 231 1 229 1
TG, GG 47 1.634 (1.035-
2.579), 0.035/
0.216
28 1.320 (0.625-
2.786), 0.466/
0.616
19 1.839 (1.028-
3.289), 0.040/
0.237
rs2082940 CC 466 1 233 1 233 1
CT 39 1.383 (0.812-
2.357), 0.233/
0.668
26 1.356 (0.642-
2.862), 0.425/
0.616
13 1.352 (0.627-
1.917), 0.442/
0.821
TT 2 5.368 (1.310-
21.997), 0.020/
0.203
0 - 2 4.885 (1.185-
20.138), 0.028/
0.237
CC 466 1 233 1 233 1
CT, TT 41 1.518 (0.918-
2.512), 0.104/
0.334
26 1.356 (0.642-
2.862), 0.425/
0.616
15 1.611 (0.813-
3.196), 0.172/
0.544
aAdjusted for baseline BMI, WHR, fasting plasma glucose and study group.
bAdjusted for baseline BMI, WHR and fasting plasma glucose.
Correction for multiple hypothesis testing was performed with FDR, denoted as q-value.
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Page 8 of 13genetic signal, independent of the variations in intron 1.
The association of the rare minor alleles of these two
SNPs with higher adiponectin levels in men, and on the
other hand, higher risk of T2DM in the total population
is contradictory. Especially so, since a non-significant
trend for lower adiponectin levels predicting higher risk
of developing T2DM was seen in our population. The
number of minor allele carriers was relatively low and
the results should therefore be interpreted with caution.
Nevertheless, the T allele of rs2241766 associates with
lower adiponectin levels [14,28,30,31] and the G allele
with T2DM related traits in several previous studies
[19-21,24].
While association between ADIPOQ promoter SNPs
and adiponectin levels have been suggested widely
[18,23,29,31-33], we did not find significant association
between rs266729 and adiponectin levels possibly due to
lack of statistical power. The results of several functional
studies suggest that rs266729 does not have influence on
the transcription efficiency [16,27,32]. On the other
hand, an important role in ADIPOQ promoter activity
was recently suggested for rs266729 and two other
promoter SNPs (rs16861194 and rs17300539) [48].
In addition, another study presents evidence that
rs266729 alters the sequence in one of the transcrip-
tional stimulatory protein (SP1) binding sites in the pro-
moter region [49]. Unfortunately, in the DPS
population, we did not genotype the promoter variant
rs17300539 for which important functional role has
been also suggested [16,48].
Significant differences were seen in 4-year change in
serum adiponectin levels according to rs16861205.
Increase in adiponectin levels was greatest in A allele
carriers and the most beneficial changes in serum adipo-
nectin concentrations were seen in A allele carriers who
were able to lose weight, while in a group of subjects
whose weight increased, genotype differences were not
seen. This may implicate that A allele carriers benefit
more of weight loss in terms of change in adiponectin
concentrations. Genotype differences were still signifi-
cant for the dominant inheritance model when 4-year
weight change was used, although the number of sub-
jects was low.
Several ADIPOQ association studies have failed to
replicate results of previous studies or have even
reported opposite effects of alleles. Possible explanation
Table 5 Association of rs16861210, rs17366568, rs2241766, rs6773957 and s2082940 with baseline serum adiponectin
levels
p/q
a p/q
b
rs16861210 GG (224) GA (12) AA (1)
All 7.76 (7.32-8.22) 10.27 (8.29-12.45) 11.79 (5.33-20.77) 0.029/0.032 0.143/0.495
GG (224) AA, AG (13)
All 7.76 (7.32-8.22) 10.38 (8.47-12.48) 0.008/0.032 0.201/0.495
rs17366568 GG (169) GA (59) AA (9)
All 8.40 (7.88-8.94) 6.90 (6.16-7.69) 6.44 (6.48-8.48) 0.003/0.032 0.893/0.840
GG (169) AA, AG (68)
All 8.40 (7.88-8.49) 6.84 (6.15-7.58) 0.0007/0.032 0.850/0.840
rs2241766 TT (224) TG (13)
All 7.82 (7.38-8.28) 9.70 (7.83-11.76) 0.056/0.032 0.020/0.279
Men
c 6.45 (5.85-7.08) 12.54 (8.49-17.37) 0.003/0.131
Women
d 8.87 (8.32-9.44) 9.38 (7.30-11.71) 0.660/0.092
rs6773957 GG (104) AG (110) AA (23)
All 7.36 (6.74-8.00) 8.12 (7.51-8.75) 9.45 (8.05-10.96) 0.016/0.032 0.711/0.840
GG (104) AA, AG (133)
All 7.35 (6.73-8.00) 8.34 (7.77-8.92) 0.021/0.032 0.559/0.840
AG, GG (214) AA (23)
All 7.76 (7.31-8.22) 9.47 (8.06-10.99) 0.022/0.032 0.772/0.840
rs2082940 CC (224) CT (13)
All 7.82 (7.38-8.28) 9.70 (7.83-11.76) 0.056/0.032 0.020/0.279
Men
e 6.45 (5.85-7.08) 12.54 (8.49-17.37) 0.003/0.131
Women
f 8.87 (8.32-9.44) 9.38 (7.30-11.71) 0.660/0.092
Data are expressed as predicted geometric mean (95% CI)- Correction for multiple hypothesis testing was performed with FDR, denoted as q-value.
a adjusted for age, sex and baseline WHR.
b sex-genotype interaction.
cTT: N = 80, TG: N = 3;
dTT: N = 144, TG: N = 10;
eCC: N = 80, CT: N = 3;
fCC: N = 144, CT: N = 10.
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various ethnic backgrounds. Moreover, the true func-
tional SNPs underlying complex traits may be rare and
population specific. Recently, Bowden at al. (2010)
demonstrated that a rare ADIPOQ variant explained
approximately 17% of the variance in plasma adiponec-
tin in Hispanic American population. Interestingly, this
variant was not observed in African American or
European American populations [50].
Since ADIPOQ alleles have shown opposite effects
even in populations with similar ethnic background and
disease status [14,51] other explanations, such as differ-
ences in participant inclusion criteria, diagnostic criteria
and study design, are also possible. As an example,
g e n e t i ce f f e c t sf o rc o m p l e xt r a i t sc a nv a r yb ya g ea n d
such interactions can even prevent replication of an
association especially in cross-sectional studies [52].
Lastly gene-gene interactions, genetic epistasis and even
epigenetic modifications may modify genetic associa-
tions. Although these phenomena are still poorly under-
stood in human, Greene et al (2009) have shown that
differences in allele frequencies and gene-gene interac-
tions can explained results where effects of gene varia-
tions are significant, but in different directions [53].
Lastly, one obvious possibility is that these findings are
simply due to chance. However, since significant asso-
ciations have been replicated in many different popula-
tions, the latter alternative seems unlikely.
The two-block LD structure of ADIPOQ with the exis-
tence of two independent genetic signals corresponding
to the haploblock structure reported earlier [22,31] was
also found in the DPS and different phenotypes were
accounted for mostly by SNPs located in separate
regions based on the LD structure of ADIPOQ. ADIPOQ
is a locus of low LD and high haplotypic diversity [54]
and it is therefore important to perform the association
studies in genetically homogeneous population with
comparatively high degree of LD. Owing to its demo-
graphic history, the Finnish population exhibits a
decrease of genetic diversity and an increase in LD
when compared with more admixed populations of cen-
tral European background and it has been speculated
that identifying genes for complex traits could be espe-
cially advantageous in this population [55]. Moreover,
the participants of the DPS study were carefully selected
and phenotyped, hence minimising the risk of false
results due to population stratification. Moreover, the
follow-up data available in DPS increases the power to
find true associations compared to studies with just sin-
g l em e a s u r e m e n to fag i v e nv a r i a b l e .T h es i z eo ft h e
DPS population, however, is moderate for genetic asso-
ciation study and we were only able to measure the
serum adiponectin levels from part of the study partici-
pants. This may weaken the power to find true associa-
tions or increase the risk of false positive findings.
Performing multiple statistical tests in genetic associa-
tion studies is likely to lead to false positive findings and
general guidelines on applying correction for multiple
comparisons or threshold values do not exist. In this
study, we applied FDR to control for the multiple
hypothesis testing and present combination of p-value
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Figure 3 Four year change in serum adiponectin levels
according to rs16861205. Data are means ± SD. Dominant
inheritance model for the whole DPS (A), for participants who lost
weight (B), and for participants who gained weight during the first
year (C). p/q value for GG genotype vs. A allele carriers, Kruskal-
Wallis test; Correction for multiple hypothesis testing was performed
with FDR, denoted as q-value.
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FDR provides an estimation of the minimum false dis-
covery rate at which the test may be called significant.
FDR was low (q < 0.1) for associations between ADI-
POQ SNPs and body weight/BMI and serum adiponec-
tin levels. However, although p value was <0.05, the
FDR was higher for the risk of T2DM in our analyses.
Nevertheless, given that our candidate gene was selected
based on solid prior information on the important role
of adiponectin as a metabolic regulator, and the study
design that enabled us to perform statistical analyses
also on longitudinal data, we believe that our results are
true associations. Again, this is further supported by the
results of earlier genetic association studies on ADIPOQ.
Conclusions
This study, performed in a homogeneous group of indi-
viduals, supported the significant role of ADIPOQ varia-
tions in conditions linked to T2DM and obesity, partly
by replicating earlier findings, but also by discovering
novel associations. New evidence for the involvement of
rs3821799 and rs6773957 in obesity was provided. Parti-
cularly, the strong association of rs6773957 with body
weight and serum adiponectin levels is interesting find-
ing as this SNP is located in the 3’UTR and could there-
fore have an effect on mRNA stability or translational
efficiency.
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